News Search Results
May 06, 2026, 07:00 ET InMode Reports First Quarter 2026 Financial Results: Quarterly GAAP Revenue of $82 Million, Represents 5% Year-Over-Year Increase
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com.Forward-Looking
More news about: InMode LTD.
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, Colorado. Intermediate dry AMD is a chronic, progressive retinal disease marked by large drusen and
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in Vision and Ophthalmology (ARVO) 2026
age-related macular degeneration (AMD). Results of the study were presented in an oral presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting in Denver, Colorado. Intermediate dry AMD is a chronic, progressive retinal disease marked by large drusen and
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology、ARVO（Association for Research in Vision and Ophthalmology）2026において、中等度加齢黄斑変性（AMD）治療薬「QA102」の経口投与に関する良好な第II相データを発表
Co., Ltd.は、中等度ドライ型加齢黄斑変性（AMD）患者を対象としたQA102の第II相臨床試験で良好な結果が得られたと発表しました。この研究結果は、コロラド州デンバーで開催されたARVO（Association for Research in Vision and Ophthalmology）2026年年次総会で口頭発表されました。 中等度ドライAMDは、大きなドルーゼンと色素変化を特徴とする慢性進行性網膜疾患であり、進行性AMDに移行する重大なリスクであります。高齢者における不可逆的失明の最も一般的な原因の一つとして、そ
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology präsentiert auf der Tagung der Association for Research in Vision and Ophthalmology (ARVO) 2026 positive Phase-II-Daten zum oralen Wirkstoff QA102 für die Behandlung der intermediären altersbedingten Makuladegeneration (AMD)
Makuladegeneration (AMD) bekannt. Die Ergebnisse der Studie wurden im Rahmen eines Vortrags auf der Jahrestagung 2026 der Association for Research in Vision and Ophthalmology (ARVO) in Denver, Colorado, vorgestellt. Die intermediäre trockene AMD ist eine chronische, fortschreitende Netzhauterkrankung, die durch
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 20:28 ET MingMed Biotechnology présente des données positives de phase II sur le QA102 oral pour le traitement de la dégénérescence maculaire liée à l'âge (DMLA) intermédiaire lors de la réunion 2026 de l'Association for Research in Vision and Ophthalmology (ARVO)
Les résultats de l'étude ont fait l'objet d'une présentation orale lors de la réunion annuelle 2026 de l'Association for Research in Vision and Ophthalmology (ARVO) qui s'est tenue à Denver, dans le Colorado. La DMLA sèche intermédiaire est une maladie rétinienne chronique et progressive, caractérisée
More news about: MingMed Biotechnology Co., Ltd
May 05, 2026, 09:15 ET Verana Health Transforms Site Selection and Patient Enrollment in Clinical Trials
difference between a study that becomes mired in problems and one that meets success."Through exclusive partnerships with the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) and the American Urological Association (AUA) Quality (AQUA)® Registry, Verana Health has access
More news about: Verana Health
May 05, 2026, 08:00 ET Assort Health Unveils Activate, the Most Widely Deployed Omni-Channel Patient Outreach Agent in Provider Groups
their care journey with personalized, two-way conversations that understand specialty-specific rules, from referral authorization requirements in ophthalmology to injection timing constraints in orthopedics. Assort's AI agents enable practices to:Close open referrals faster by
More news about: Assort Health
May 04, 2026, 10:00 ET SightMD Physicians Recognized Among 2026 Super Doctors® and Rising Stars
allows us to continuously elevate the standard of care."SightMD New York is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer,
More news about: SightMD
May 04, 2026, 08:40 ET Parker Waichman LLP Files Lawsuit on behalf of South Carolina Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks.A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
May 04, 2026, 07:30 ET Keenova Launches New Consumer Campaign for Dupuytren's Contracture: Don't Be a Viking
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
May 04, 2026, 07:00 ET Ascidian Completes Dose Escalation Portion of Phase 1/2 STELLAR Trial of ACDN-01 for Stargardt Disease and Announces Expanded Clinical Study Plans
this disease," said Mark Pennesi, M.D., Ph.D., FARVO, Chief Medical Officer at the Retina Foundation of Dallas and Adjunct Professor of Ophthalmology at the Oregon Health & Science University Casey Eye Institute. "With adult dose escalation complete and pediatric subjects now enrolling, we
More news about: Ascidian Therapeutics
![New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]](https://mma.prnewswire.com/media/1986460/Specialised_Therapeutics_Logo.jpg?w=300){kind=logo}
May 03, 2026, 12:00 ET New First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]
unmet need. The company's broad therapeutic portfolio currently includes novel agents in oncology, haematology, CNS, neurology, endocrinology, ophthalmology and supportive care, although it is not confined to these areas. Additional information can be found at
More news about: Specialised Therapeutics
May 03, 2026, 09:09 ET Everads Announces Publication of First-in-Human Clinical Data for Its Suprachoroidal Injector in Ophthalmology Science and Three Presentations at ARVO 2026
treatment of retinal diseases, today announced publication of clinical data from its first-in-human trial in Ophthalmology Science, the peer-reviewed journal of the American Academy of Ophthalmology [https://doi.org/10.1016/j.xops.2026.101185].
More news about: Everads Therapy
May 03, 2026, 08:43 ET Spinogenix to Present Preclinical Results at ARVO 2026 Demonstrating Neuroprotective Effects of Tazbentetol in Glaucoma and Diabetic Retinopathy Models
neuroprotective effects of tazbentetol (SPG302) in glaucoma and diabetic retinopathy (DR) models at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The presentation builds on the peer-reviewed glaucoma research published recently in
More news about: Spinogenix
May 01, 2026, 20:52 ET US Startup PerZeption Inc. Announces Collaboration with Alcon Research
evaluation.This joint effort highlights a shared dedication to advancing ophthalmology research and developing precise tools for visual assessment. The ARVO annual meeting serves as the world's foremost event for ophthalmology research, offering a vital platform for sharing scientific breakthroughs
More news about: PerZeption
May 01, 2026, 16:00 ET Foundation Fighting Blindness Names Dr. Eric Pierce as the Recipient of Its Highest Honor, the Llura Liggett Gund Award
treatments, and in some cases seeing clearly enough to recognize the faces of family and friends.Dr. Pierce, the William F. Chatlos Professor of Ophthalmology at Harvard Medical School and Director of the Ocular Genomics Institute at Massachusetts Eye and Ear, has identified genes responsible for multiple
More news about: Foundation Fighting Blindness
May 01, 2026, 10:00 ET SightMD Pennsylvania Welcomes A'sha M. Brown, MD to Wyomissing and Pottsville Locations
Medicine, followed by an ophthalmology residency at Drexel University, where she served as co-chief resident. She went on to complete a fellowship in Medical Retina and Uveitis at Emory University's Emory Eye Center. She is board-certified by the American Board of Ophthalmology and is an active member
More news about: SightMD
May 01, 2026, 07:30 ET Keenova Presents a New TERLIVAZ® (terlipressin) Clinical Analysis at Digestive Disease Week
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics
May 01, 2026, 00:23 ET Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences
Associate Professor-in-Residence of Ophthalmology, Stein Eye Institute, David Geffen School of Medicine, University of California, Los Angeles (UCLA), USATime: 7:45pm MTPresentations at Association for Research in Vision and Ophthalmology – May 3-7, 2026, in Denver, Colorado.
More news about: Kodiak Sciences Inc.
Apr 30, 2026, 10:00 ET SightMD Wins "Best of the Boro" Honors for Ophthalmology and LASIK Surgery
www.SightMD.com or call 855.295.4144.SightMD New York is actively seeking ophthalmology professionals who are interested in joining its outstanding team. If you are an ophthalmology practice owner interested in merging or selling your practice, please contact the Chief Medical Officer,
More news about: SightMD
Apr 30, 2026, 09:15 ET Verana Health Introduces World's Largest Real-World Dataset for Prostate Cancer
artificial intelligence to unlock the true potential of real-world data. With exclusive access to the world's largest patient data sources in oncology, ophthalmology, neurology, and urology. Verana Health is powering real-world evidence generation. Clinicians utilize these insights to improve the quality of care
More news about: Verana Health
Apr 30, 2026, 09:00 ET Astellas to Highlight New Findings for Geographic Atrophy at ARVO 2026 Annual Meeting
"Astellas") today announced new research insights for geographic atrophy (GA) that will be presented at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO), May 3-7, Denver, Colorado.
More news about: Astellas Pharma Inc.
Apr 30, 2026, 07:47 ET NAMSA and Lexitas Announce Strategic Partnership to Deliver End-to-End Ophthalmic Medical Device Development
Sponsors gain a single, accountable partner through all stages of product development, with Lexitas' dedicated ophthalmology expertise embedded in NAMSA's end-to-end MedTech development platformTOLEDO, Ohio and DURHAM, N.C., April
More news about: NAMSA
Apr 30, 2026, 07:00 ET Keenova Therapeutics to Report First Quarter 2026 Financial Results on May 12, 2026
diversified brands portfolio, which is focused across a wide range of specialty therapeutic areas of significant unmet need. These include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care.Headquartered in Dublin, Ireland, Keenova
More news about: Keenova Therapeutics